Atlas FDA

CRCDx RAS Mutation Detection Assay Kit

FDA premarket approval P220005 · decided 2023-09-29

Approval details

PMA number
P220005
Trade name
CRCDx RAS Mutation Detection Assay Kit
Generic name
Somatic gene mutation detection system
Applicant
Entrogen, Inc.
Date received
2022-04-20
Decision date
2023-09-29
Days to decision
527 days
Decision code
APPR
Product code
OWD
Advisory committee
Pathology
Expedited review
No
Location
Woodland Hills, CA
Statement
Approval for the CRCdx® RAS Mutation Detection Kit. The device is a qualitative real-time PCR in vitro diagnostic test intended for the detection of 35 variants of KRAS and NRAS exon 2, 3, 4 somatic mutations in genomic DNA extracted from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) tissue samples. The test is intended as a companion diagnostic (CDx) to aid in the identification of colorectal cancer (mCRC) patients who may benefit from treatment with Vectibix (panitumumab) ba

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.